{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:32:43Z","timestamp":1793421163186,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.06.050","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T15:05:43Z","timestamp":1783263943000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["System-level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated With High One-year Survival and Reduced Cost"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-9419","authenticated-orcid":false,"given":"Shernan G.","family":"Holtan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal","family":"Mallhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0072-2183","authenticated-orcid":false,"given":"Trish","family":"Boersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Pleskow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora","family":"Yoerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Aungst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5199-1997","authenticated-orcid":false,"given":"Nataliya","family":"Buxbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Higman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-3065","authenticated-orcid":false,"given":"Marco L.","family":"Davila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2026.06.050_bib0001","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/bloodadvances.2023011033","article-title":"Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective","volume":"8","author":"Maziarz","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.050_bib0002","doi-asserted-by":"crossref","first-page":"542.e1","DOI":"10.1016\/j.jtct.2024.01.084","article-title":"Healthcare resource utilization and cost associated with allogeneic hematopoietic stem cell transplantation: a scoping review","volume":"30","author":"Kim","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.06.050_bib0003","unstructured":"Census.gov, Quick facts: Buffalo, New York. https:\/\/www.census.gov\/quickfacts\/fact\/table\/buffalocitynewyork\/PST045224, 2024. Assessed January 22, 2026."},{"issue":"1","key":"10.1016\/j.jtct.2026.06.050_bib0004","article-title":"A community-university run conference as a catalyst for addressing health disparities in an urban community","volume":"6","author":"Murphy","year":"2022","journal-title":"J Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.050_bib0005","article-title":"Cancer incidence trends in New York State and associations with common population-level exposures 2010-2018: an ecological study","volume":"14","author":"Yuan","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.050_bib0006","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1182\/bloodadvances.2025018340","article-title":"CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 Study","volume":"10","author":"Artz","year":"2026","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.050_bib0007","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/bloodadvances.2021004319","article-title":"The simplified comorbidity index: a new tool for prediction of nonrelapse mortality in allo-HCT","volume":"6","author":"Shouval","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.050_bib0008","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtct.2025.07.004","article-title":"Allogeneic hematopoietic cell donor selection: contemporary guidelines from the NMDP\/CIBMTR","volume":"31","author":"Jimenez Jimenez","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.050_bib0009","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/s41375-025-02724-1","article-title":"Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings","volume":"39","author":"Schetelig","year":"2025","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.050_bib0010","doi-asserted-by":"crossref","first-page":"345.e1","DOI":"10.1016\/j.jtct.2025.10.001","article-title":"Search summary score: a global measure to predict matched unrelated stem cell donor availability","volume":"32","author":"Fingerson","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.050_bib0011","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2018.02.006","article-title":"Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most","volume":"24","author":"Shaw","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.050_bib0012","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41409-022-01577-x","article-title":"Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the acute leukemia working party of the EBMT","volume":"57","author":"Battipaglia","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jtct.2026.06.050_bib0013","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/bloodadvances.2025016236","article-title":"Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis","volume":"9","author":"Aljawai","year":"2025","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.050_bib0014","doi-asserted-by":"crossref","first-page":"1090.e1","DOI":"10.1016\/j.jtct.2024.08.007","article-title":"Melphalan dose in combination with fludarabine affects gastrointestinal toxicity and graft-versus-host disease after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndromes","volume":"30","author":"Albanyan","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.050_bib0015","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41409-025-02594-2","article-title":"Cytokine release syndrome: implications for transplant outcomes in haploidentical and HLA-matched HSCT using PTCy","volume":"60","author":"Benavente","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.050_bib0016","doi-asserted-by":"crossref","first-page":"515.e1","DOI":"10.1016\/j.jtct.2023.05.008","article-title":"Tocilizumab for cytokine release syndrome management after haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"29","author":"Yao","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.050_bib0017","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.050_bib0018","doi-asserted-by":"crossref","first-page":"363.e1","DOI":"10.1016\/j.jtct.2025.02.024","article-title":"Evaluation of immunosuppression levels and risk of graft-versus-host disease in allogeneic blood or marrow transplantation with post-transplantation cyclophosphamide","volume":"31","author":"Lee","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.050_bib0019","doi-asserted-by":"crossref","first-page":"500.e1","DOI":"10.1016\/j.jtct.2022.05.039","article-title":"Mycophenolate mofetil: a friend or a foe with post-transplantation cyclophosphamide and tacrolimus prophylaxis in HLA-matched donors?","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.050_bib0020","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1016\/j.jtct.2024.02.010","article-title":"Reducing PTCY dose in patients receiving CAST for GvHD prevention results in accelerated engraftment at the cost of higher incidence of GvHD","volume":"30","author":"Andres-Suarez Londono","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.050_bib0021","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jtct.2026.06.050_bib0022","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/bloodadvances.2018017343","article-title":"Amphiregulin modifies the Minnesota acute graft-versus-host disease risk score: results from BMT CTN 0302\/0802","volume":"2","author":"Holtan","year":"2018","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.jtct.2026.06.050_bib0023","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/bloodadvances.2023009929","article-title":"The utility of biomarkers in acute GVHD prognostication","volume":"7","author":"Spyrou","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.050_bib0024","article-title":"Fecal calprotectin as a diagnostic and prognostic biomarker for gastrointestinal graft versus host disease: a systematic review of literature","volume":"11","author":"Malik","year":"2019","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.050_bib0025","doi-asserted-by":"crossref","first-page":"509.e1","DOI":"10.1016\/j.jtct.2023.05.021","article-title":"Phase II, open-label clinical trial of urinary-derived human chorionic gonadotropin\/epidermal growth factor for life-threatening acute graft-versus-host disease","volume":"29","author":"Holtan","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.050_bib0026","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2017-11-815746","article-title":"Alpha(1)-antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease","volume":"131","author":"Magenau","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.06.050_bib0027","article-title":"Vedolizumab for acute gastrointestinal graft-versus-host disease: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.050_bib0028","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jtct.2021.05.004","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2020 treatment of chronic GVHD report","volume":"27","author":"DeFilipp","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.050_bib0029","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2013-08-520072","article-title":"Plasma CXCL9 elevations correlate with chronic GVHD diagnosis","volume":"123","author":"Kitko","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.050_bib0030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy: a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"25","key":"10.1016\/j.jtct.2026.06.050_bib0031","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.jtct.2026.06.050_bib0032","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.24.00184","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","volume":"42","author":"Shaffer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.050_bib0033","doi-asserted-by":"crossref","first-page":"695.e1","DOI":"10.1016\/j.jtct.2022.07.021","article-title":"Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.050_bib0034","doi-asserted-by":"crossref","first-page":"74.e1","DOI":"10.1016\/j.jtct.2025.09.048","article-title":"Post-transplant cyclophosphamide improves survival in HLA-DPB1 mismatched unrelated donor allogeneic transplantation","volume":"32","author":"McCurdy","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"24","key":"10.1016\/j.jtct.2026.06.050_bib0035","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.050_bib0036","doi-asserted-by":"crossref","first-page":"113","DOI":"10.36469\/9814","article-title":"Estimating the burden of cost in chronic graft-versus-host disease: a human capital approach","volume":"4","author":"Jones","year":"2017","journal-title":"J Health Econ Outcomes Res"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.050_bib0037","doi-asserted-by":"crossref","first-page":"637.e1","DOI":"10.1016\/j.jtct.2023.06.013","article-title":"Estimating the lifetime medical cost burden of an allogeneic hematopoietic cell transplantation patient","volume":"29","author":"Maziarz","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.06.050_bib0038","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221080739","article-title":"Outpatient allogeneic hematopoietic stem-cell transplantation: a review","volume":"13","author":"Gomez-Almaguer","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"14","key":"10.1016\/j.jtct.2026.06.050_bib0039","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.3390\/healthcare13141648","article-title":"Hospital at home following allogeneic hematopoietic stem cell transplantation: an economic analysis","volume":"13","author":"Mishra","year":"2025","journal-title":"Healthcare (Basel)"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:27:30Z","timestamp":1793420850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"alternative-id":["S2666636726005294"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.050","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"System-level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated With High One-year Survival and Reduced Cost","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}